Table II.
Group | GSH (ng/ml) | TNF-α (ng/l) | MDA (nmol/mg prot) |
---|---|---|---|
C1 | 0.78±0.13 | 119.39±34.81 | 0.53±0.09 |
M1 | 0.57±0.06a | 343.83±20.61a | 1.11±0.10a |
T1 | 0.71±0.06b | 275.93±34.12b | 0.90±0.06b |
C2 | 0.67±0.05 | 162.68±13.50 | 0.51±0.04 |
M2 | 0.48±0.07b,c | 427.83±53.59b,c | 1.45±0.15b,c |
T2 | 0.59±0.05d | 308.64±25.62d | 0.98±0.22d |
Results are presented as the mean ± standard deviation. Tumor necrosis factor-α (TNF-α) and malondialdehyde (MDA) levels in the model groups (M1 and M2) were higher than those in the control groups (C1 and C2), respectively (P<0.05), and those in glutamine treatment groups (T1 and T2) were lower compared with those in the model group, at each time-point (P<0.05). The glutathione (GSH) level in the model group was significantly lower than that in the normal control at the same time-point (P<0.05); whereas that in the glutamine treatment group was significantly higher than that in the model group (P<0.05).
P<0.05 compared with group C1;
P<0.05 compared with group M1;
P<0.05 compared with group C2;
P<0.05 compared with group M2.